펩티드 합성 : 세계 시장 점유율과 순위, 전체 판매, 수요 예측(2025-2031년)

The global market for Peptide Synthesis was estimated to be worth US$ 699 million in 2024 and is forecast to a readjusted size of US$ 1094 million by 2031 with a CAGR of 6.7% during the forecast period 2025-2031.

Peptide synthesis refers to the process of linking multiple amino acids into a peptide chain in a specified sequence by chemical or biochemical methods. These peptides may serve as therapeutics, diagnostic reagents, biomarkers, or research tools. Peptides are generally shorter than proteins - most often composed of no more than 40-60 amino acid residues - though their structures can be complex, including non-natural or modified amino acids, cyclizations, conjugations with chemical moieties or labels. The main techniques for peptide synthesis include solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid/convergent methods, enzymatic or recombinant expression methods. The synthetic workflow typically involves protecting and deprotecting amino acids, peptide bond formation (coupling), support/resin anchoring or carrier systems, purification (such as chromatographic steps, precipitations, etc.), and rigorous quality control (structure confirmation, stereochemical purity, impurity/residual solvent analysis). With the rapid expansion of peptide-based drugs, diagnostics, and cosmetic applications, combined with growing demand for high specificity, low toxicity, and strong biocompatibility, peptide synthesis has become a cornerstone in biopharma and life science R&D.

The peptide synthesis market currently stands at a multi-accelerated inflection point. On one side, peptide-based therapeutics are being increasingly recognized in fields such as chronic diseases, metabolic disorders, oncology, and neurodegeneration: their high specificity, low systemic toxicity, and novel targeting mechanisms make them promising where traditional small molecules or large proteins struggle. On another side, governments and regulatory agencies in many countries (including the U.S., EU, Japan, China, etc.) are introducing policies that support innovation, streamline approval pathways for novel peptides or peptide/oligonucleotide (TIDES) drugs, and shorten clinical trial and regulatory review timelines, thereby enlarging market opportunity for peptide synthesis providers. On the technical front, continued progress in solid-phase synthesis (SPPS), liquid-phase methods (LPPS), hybrid / convergent synthesis, and enhanced capabilities for complex structures (including non-natural amino acids, cyclization, peptide-drug conjugates) are pushing the market toward larger scale, higher quality, and greater structural diversity. In addition, downstream CDMO/CRO outsourcing demand is rising sharply: drug developers are increasingly preferring to externalize process development, scale-up, and clinical/registration production to specialized synthesis/manufacturing entities to reduce capital burden and risk. Emerging economies (e.g. China, India, South Korea) are also providing strong growth drivers due to their rising healthcare needs, biotech investment, lower manufacturing cost bases, and favorable policy incentives.

However, the peptide synthesis market is not without substantial challenges and risks. First, synthesizing long or complex peptides (with modifications, non-natural residues, cyclization, hydrophobic sequences etc.) amplifies problems of low coupling efficiency, incomplete reactions, racemization, side-product formation - these reduce yield and make purification expensive and difficult. Second, the supply chain stability and cost volatility for upstream raw materials (high-purity protected amino acids, specialized coupling reagents, protective groups, rare or synthetic modified amino acids) is high; environmental / safety laws regulating chemical reagents and solvents impose increasing constraints. Third, downstream purification and quality control steps (chromatography, removal of residual reagents/protection groups/solvents, structure confirmation, stereochemical purity) require heavy equipment investment, long cycles, and high operating costs, particularly at clinical/commercial scale. Regulatory risk is also real: differing national definitions of peptides vs biologics (or other categories), regulatory standards, and environmental / chemical safety policies may shift, increasing compliance cost or causing delays. Finally, competitive pressures and pricing squeeze are intensifying, especially among CDMOs / synthesis service providers, and in emerging markets focusing on low cost; maintaining high quality, speed, and regulatory compliance becomes a differentiator but also a cost center.

Downstream demand is evolving in several concurrent directions. Therapeutic peptides continue to be the largest pull: more peptide drugs are gaining regulatory approval, and the R&D pipeline is expanding, especially in metabolic disease (e.g. obesity, diabetes), oncology, endocrine regulation, and infectious diseases. In several disease areas, peptide-drug conjugates and peptide vaccines are emerging as key focus areas. Beyond therapeutics, diagnostic and imaging labelled peptides are growing demand, e.g. biomarkers, in vitro diagnostics (IVD) and radiolabelled or fluorescent labelled small peptides, especially in precision medicine. The cosmetics / beauty sector is also actively introducing peptides with anti-aging, repair, collagen-boosting, antioxidative functionalities, with rising consumer and brand expectations for natural or bio-active, safety validated ingredients. Research and basic science needs remain stable, being driven by automation and high-throughput synthesis tools, giving academic institutions and biotech startups need for more flexible, fast, custom peptide synthesis services. Overall, downstream demand is trending toward more complex structures / high modifications / higher purity / more individualized use, and demands for faster turnaround and higher service quality.

This report aims to provide a comprehensive presentation of the global market for Peptide Synthesis, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peptide Synthesis by region & country, by Type, and by Application.

The Peptide Synthesis market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Synthesis.

Market Segmentation

By Company

• Bachem
• PolyPeptide
• CordenPharma
• AmbioPharm
• USV Peptides
• Thermofischer
• Bio Basic
• JPT
• Genscript
• Xinbang Pharma
• ScinoPharm
• SN Biopharm
• CBL
• Piramal Pharma
• CPC Scientific
• Shenzhen Hanyu

Segment by Type

• APIs and Intermediates
• Peptide preparations

Segment by Application

• Commercial
• Academic Research

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Peptide Synthesis company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Revenue of Peptide Synthesis in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Revenue of Peptide Synthesis in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Peptide Synthesis Product Introduction
• 1.2 Global Peptide Synthesis Market Size Forecast (2020-2031)
• 1.3 Peptide Synthesis Market Trends & Drivers
  • 1.3.1 Peptide Synthesis Industry Trends
  • 1.3.2 Peptide Synthesis Market Drivers & Opportunity
  • 1.3.3 Peptide Synthesis Market Challenges
  • 1.3.4 Peptide Synthesis Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Peptide Synthesis Players Revenue Ranking (2024)
• 2.2 Global Peptide Synthesis Revenue by Company (2020-2025)
• 2.3 Key Companies Peptide Synthesis Manufacturing Base Distribution and Headquarters
• 2.4 Key Companies Peptide Synthesis Product Offered
• 2.5 Key Companies Time to Begin Mass Production of Peptide Synthesis
• 2.6 Peptide Synthesis Market Competitive Analysis
  • 2.6.1 Peptide Synthesis Market Concentration Rate (2020-2025)
  • 2.6.2 Global 5 and 10 Largest Companies by Peptide Synthesis Revenue in 2024
  • 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Synthesis as of 2024)
• 2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 APIs and Intermediates
  • 3.1.2 Peptide preparations
• 3.2 Global Peptide Synthesis Sales Value by Type
  • 3.2.1 Global Peptide Synthesis Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Peptide Synthesis Sales Value, by Type (2020-2031)
  • 3.2.3 Global Peptide Synthesis Sales Value, by Type (%) (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 Commercial
  • 4.1.2 Academic Research
• 4.2 Global Peptide Synthesis Sales Value by Application
  • 4.2.1 Global Peptide Synthesis Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Peptide Synthesis Sales Value, by Application (2020-2031)
  • 4.2.3 Global Peptide Synthesis Sales Value, by Application (%) (2020-2031)

5 Segmentation by Region

• 5.1 Global Peptide Synthesis Sales Value by Region
  • 5.1.1 Global Peptide Synthesis Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Peptide Synthesis Sales Value by Region (2020-2025)
  • 5.1.3 Global Peptide Synthesis Sales Value by Region (2026-2031)
  • 5.1.4 Global Peptide Synthesis Sales Value by Region (%), (2020-2031)
• 5.2 North America
  • 5.2.1 North America Peptide Synthesis Sales Value, 2020-2031
  • 5.2.2 North America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
• 5.3 Europe
  • 5.3.1 Europe Peptide Synthesis Sales Value, 2020-2031
  • 5.3.2 Europe Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
• 5.4 Asia Pacific
  • 5.4.1 Asia Pacific Peptide Synthesis Sales Value, 2020-2031
  • 5.4.2 Asia Pacific Peptide Synthesis Sales Value by Region (%), 2024 VS 2031
• 5.5 South America
  • 5.5.1 South America Peptide Synthesis Sales Value, 2020-2031
  • 5.5.2 South America Peptide Synthesis Sales Value by Country (%), 2024 VS 2031
• 5.6 Middle East & Africa
  • 5.6.1 Middle East & Africa Peptide Synthesis Sales Value, 2020-2031
  • 5.6.2 Middle East & Africa Peptide Synthesis Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Peptide Synthesis Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Peptide Synthesis Sales Value, 2020-2031
• 6.3 United States
  • 6.3.1 United States Peptide Synthesis Sales Value, 2020-2031
  • 6.3.2 United States Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Peptide Synthesis Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Peptide Synthesis Sales Value, 2020-2031
  • 6.4.2 Europe Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Peptide Synthesis Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Peptide Synthesis Sales Value, 2020-2031
  • 6.5.2 China Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Peptide Synthesis Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Peptide Synthesis Sales Value, 2020-2031
  • 6.6.2 Japan Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Peptide Synthesis Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Peptide Synthesis Sales Value, 2020-2031
  • 6.7.2 South Korea Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Peptide Synthesis Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Peptide Synthesis Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Peptide Synthesis Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Peptide Synthesis Sales Value, 2020-2031
  • 6.9.2 India Peptide Synthesis Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Peptide Synthesis Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Bachem
  • 7.1.1 Bachem Profile
  • 7.1.2 Bachem Main Business
  • 7.1.3 Bachem Peptide Synthesis Products, Services and Solutions
  • 7.1.4 Bachem Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.1.5 Bachem Recent Developments
• 7.2 PolyPeptide
  • 7.2.1 PolyPeptide Profile
  • 7.2.2 PolyPeptide Main Business
  • 7.2.3 PolyPeptide Peptide Synthesis Products, Services and Solutions
  • 7.2.4 PolyPeptide Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.2.5 PolyPeptide Recent Developments
• 7.3 CordenPharma
  • 7.3.1 CordenPharma Profile
  • 7.3.2 CordenPharma Main Business
  • 7.3.3 CordenPharma Peptide Synthesis Products, Services and Solutions
  • 7.3.4 CordenPharma Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.3.5 CordenPharma Recent Developments
• 7.4 AmbioPharm
  • 7.4.1 AmbioPharm Profile
  • 7.4.2 AmbioPharm Main Business
  • 7.4.3 AmbioPharm Peptide Synthesis Products, Services and Solutions
  • 7.4.4 AmbioPharm Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.4.5 AmbioPharm Recent Developments
• 7.5 USV Peptides
  • 7.5.1 USV Peptides Profile
  • 7.5.2 USV Peptides Main Business
  • 7.5.3 USV Peptides Peptide Synthesis Products, Services and Solutions
  • 7.5.4 USV Peptides Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.5.5 USV Peptides Recent Developments
• 7.6 Thermofischer
  • 7.6.1 Thermofischer Profile
  • 7.6.2 Thermofischer Main Business
  • 7.6.3 Thermofischer Peptide Synthesis Products, Services and Solutions
  • 7.6.4 Thermofischer Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.6.5 Thermofischer Recent Developments
• 7.7 Bio Basic
  • 7.7.1 Bio Basic Profile
  • 7.7.2 Bio Basic Main Business
  • 7.7.3 Bio Basic Peptide Synthesis Products, Services and Solutions
  • 7.7.4 Bio Basic Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.7.5 Bio Basic Recent Developments
• 7.8 JPT
  • 7.8.1 JPT Profile
  • 7.8.2 JPT Main Business
  • 7.8.3 JPT Peptide Synthesis Products, Services and Solutions
  • 7.8.4 JPT Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.8.5 JPT Recent Developments
• 7.9 Genscript
  • 7.9.1 Genscript Profile
  • 7.9.2 Genscript Main Business
  • 7.9.3 Genscript Peptide Synthesis Products, Services and Solutions
  • 7.9.4 Genscript Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.9.5 Genscript Recent Developments
• 7.10 Xinbang Pharma
  • 7.10.1 Xinbang Pharma Profile
  • 7.10.2 Xinbang Pharma Main Business
  • 7.10.3 Xinbang Pharma Peptide Synthesis Products, Services and Solutions
  • 7.10.4 Xinbang Pharma Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.10.5 Xinbang Pharma Recent Developments
• 7.11 ScinoPharm
  • 7.11.1 ScinoPharm Profile
  • 7.11.2 ScinoPharm Main Business
  • 7.11.3 ScinoPharm Peptide Synthesis Products, Services and Solutions
  • 7.11.4 ScinoPharm Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.11.5 ScinoPharm Recent Developments
• 7.12 SN Biopharm
  • 7.12.1 SN Biopharm Profile
  • 7.12.2 SN Biopharm Main Business
  • 7.12.3 SN Biopharm Peptide Synthesis Products, Services and Solutions
  • 7.12.4 SN Biopharm Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.12.5 SN Biopharm Recent Developments
• 7.13 CBL
  • 7.13.1 CBL Profile
  • 7.13.2 CBL Main Business
  • 7.13.3 CBL Peptide Synthesis Products, Services and Solutions
  • 7.13.4 CBL Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.13.5 CBL Recent Developments
• 7.14 Piramal Pharma
  • 7.14.1 Piramal Pharma Profile
  • 7.14.2 Piramal Pharma Main Business
  • 7.14.3 Piramal Pharma Peptide Synthesis Products, Services and Solutions
  • 7.14.4 Piramal Pharma Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.14.5 Piramal Pharma Recent Developments
• 7.15 CPC Scientific
  • 7.15.1 CPC Scientific Profile
  • 7.15.2 CPC Scientific Main Business
  • 7.15.3 CPC Scientific Peptide Synthesis Products, Services and Solutions
  • 7.15.4 CPC Scientific Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.15.5 CPC Scientific Recent Developments
• 7.16 Shenzhen Hanyu
  • 7.16.1 Shenzhen Hanyu Profile
  • 7.16.2 Shenzhen Hanyu Main Business
  • 7.16.3 Shenzhen Hanyu Peptide Synthesis Products, Services and Solutions
  • 7.16.4 Shenzhen Hanyu Peptide Synthesis Revenue (US$ Million) & (2020-2025)
  • 7.16.5 Shenzhen Hanyu Recent Developments

8 Industry Chain Analysis

• 8.1 Peptide Synthesis Industrial Chain
• 8.2 Peptide Synthesis Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Peptide Synthesis Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Peptide Synthesis Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer